What does Epithalon stack well with?

For female physiology protocols, Epithalon pairs with compounds on complementary pathways: Oxytocin, Kisspeptin, GHK-Cu. These pairings are selected because they engage independent receptor systems from Epithalon's primary mechanism (Identified by Khavinson in St), producing additive or synergistic effects rather than receptor competition.

What is the regulatory status of Epithalon?

Epithalon regulatory status: Unapproved in the United States; WADA status not specifically listed; research level multi-decade russian research; long-running human cohort studies. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For female hormonal and cyclical use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

What are the safety considerations for Epithalon?

Outstanding safety profile in human studies extending to 15-year follow-up. No reported serious adverse events. Cycle-based dosing is standard. For female hormonal and cyclical use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. Epithalon's Very short (minutes) pharmacokinetic profile and subq/intranasal administration route influence the side-effect profile in predictable ways.

How does Epithalon compare to Oxytocin and Kisspeptin?

Epithalon (Pineal-derived tetrapeptide, Very short (minutes) half-life, 5-10 mg typical dose) differs from peers in the comparison table above. The principal points of difference relative to Oxytocin and Kisspeptin are mechanism, half-life, and target system. The full comparison is in the table above; specific stack selection depends on which dimension matters for the application.

What route should I use for Epithalon?

Epithalon is delivered by subq/intranasal. The intranasal route is preferred for compounds targeting the central nervous system because it bypasses the BBB via the olfactory pathway. The choice depends on target system and convenience.

Home/ Compounds/ Epithalon

Epithalon

Women's Health

Cycle-aware, fertility-aware, perimenopause-aware: Epithalon is evaluated by women's-health clinicians on multiple axes. Identified by Khavinson in St Petersburg. Stimulates telomerase activity in somatic cells, with downstream effects on telomere length over multi-year cycles. Normalises age-related decline in pineal melatonin output. Putative epigenetic effects on aging-clock methylation patterns are an active area of investigation.. The compound's pineal-derived tetrapeptide pharmacology produces measurable effects on the systems women's-health practice cares about — cycle regularity, mood, bone density, cardiovascular tone, and the perimenopausal transition. Each is examined in the sections below.

Female Physiology Applications

MenopauseMood (Cycle-Related)Bone DensityBody Composition (Female)Libido (Female)

Key Takeaways

Female-physiology lens: Epithalon response varies across follicular and luteal phases for premenopausal users; integrates with HRT in perimenopause and postmenopause.
Mechanism: Identified by Khavinson in St.
Female monitoring: cycle-day-appropriate estradiol, progesterone, FSH, LH, prolactin, TSH, bone markers; pregnancy contraindication is default.
Female dose: 5-10 mg 1x daily for 10-20 day cycles, 1-2x yearly via subq/intranasal; cycle-phase tracking for 1-2 cycles.
Female-physiology stack partners: Oxytocin, Kisspeptin, GHK-Cu.

Female Physiology Mechanism

Cyclical hormone background shapes how women experience Epithalon. Identified by Khavinson in St. Petersburg. Stimulates telomerase activity in somatic cells, with downstream effects on telomere length over multi-year cycles. Normalises age-related decline in pineal melatonin output. Putative epigenetic effects on aging-clock methylation patterns are an active area of investigation. For premenopausal users, phase-aware tracking across 1-2 cycles informs the schedule; for perimenopausal users, HRT integration is the dominant question; for postmenopausal users, bone density and cardiovascular tone become the priority considerations.

Perimenopause and menopause integration

For women in the perimenopausal or post-menopausal window, Epithalon is most effective when integrated with the broader hormonal picture — HRT (estrogen, progesterone, sometimes testosterone), bone-density support, and cardiometabolic monitoring. Many compounds in this category produce stronger effects in this window precisely because the surrounding hormonal landscape is changing.

Bone density and cardiovascular signalling

Two areas where female physiology diverges sharply post-menopause are bone remodelling and cardiovascular tone. Epithalon's effect on these systems is one of the underweighted but practically important considerations for women using peptides through the menopausal transition. Bone-marker labs (CTX, P1NP) and cardiovascular indices (lipids, blood pressure, hsCRP) provide a tractable monitoring framework.

Cyclical and hormonal context

Female physiology is cyclical in a way that male physiology is not, and Epithalon's effects often vary across follicular versus luteal phase. The compound's pharmacology is directly affected by the cyclical hormone background. Pre-menopausal users should expect to track response by cycle phase for one or two cycles before settling on a fixed schedule.

Female Physiology Applications

Autoimmune Support

In the perimenopausal window, Epithalon for autoimmune support produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.

Skin Health

Skin Health is one of the dimensions on which women track Epithalon response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.

Endometriosis Support

For endometriosis support in female users, Epithalon is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.

Libido (Female)

In the perimenopausal window, Epithalon for libido (female) produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	5-10 mg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	3-10 mg	4–6 weeks initial cycle
Women's Health focus	SubQ	5-10 mg	1x daily for 10-20 day cycles, 1-2x yearly
Maintenance phase	SubQ	4-10 mg	Ongoing with periodic pauses

Dose timing for Epithalon is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Epithalon stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from women's-health clinicians.

Epithalon + Oxytocin: Activates oxytocin receptors (OXTR) peripherally (uterine smooth muscle, mammary alveoli) and centrally (amygdala, hypothalamus, ventral tegmentum). Pairs naturally with Epithalon's mechanism in female physiology protocols.
Epithalon + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with Epithalon's mechanism in female physiology protocols.
Epithalon + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with Epithalon's mechanism in female physiology protocols.
Epithalon + PT-141: Activates MC4R in the hypothalamus and other CNS regions involved in sexual response. Pairs naturally with Epithalon's mechanism in female physiology protocols.

Safety & Regulatory Status

WADA: Not specifically listed FDA: Unapproved Research: Multi-decade Russian research; long-running human cohort studies

Outstanding safety profile in human studies extending to 15-year follow-up. No reported serious adverse events. Cycle-based dosing is standard.

Lens-specific safety considerations for female physiology use of Epithalon: Outstanding safety profile in human studies extending to 15-year follow-up. No reported serious adverse events. Cycle-based dosing is standard. Additional female physiology monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Khavinson et al. — Epithalon telomerase activation

PMID 12937674

Supporting

Pineal peptide preparation Epithalamin and Epithalon: anti-aging effects

PMID 12937680

Epithalon vs Related Peptides

Compound	Profile	Onset	Best For
Epithalon	Pineal-derived tetrapeptide	Very short (minutes)	Women's Health
Oxytocin	Posterior pituitary nonapeptide	~1-6 min plasma; CNS longer	The 'bonding hormone' — a posterior pituitary nonapeptide with effects on uterine contraction, lactation, and a wide range of social and sexual behaviour via central oxytocin receptors
Kisspeptin	Hypothalamic upstream regulator of GnRH	~28 min IV	The upstream master regulator of GnRH neurons — driving the entire HPG axis from above
PT-141	Melanocortin receptor agonist	~2-3 hr	An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women

Frequently Asked Questions

How will Epithalon interact with my cycle?

For pre-menopausal users, response to Epithalon often varies across follicular and luteal phases. The first 1–2 cycles should be used to track response by phase before settling on a fixed schedule. The compound's pharmacology is directly modulated by cyclical hormones, making phase-aware dosing particularly important.

Can I use Epithalon alongside HRT?

Yes, in most cases. Integration with HRT — estrogen, progesterone, sometimes testosterone — is additive rather than competitive for most peptide compounds. Coordinating with a HRT-prescribing physician on dose timing and monitoring is the standard approach.

Does Epithalon affect bone density?

Several peptide compounds have measurable effects on bone-remodelling markers, particularly relevant for post-menopausal users. Where Epithalon specifically engages this pathway, paired pre-post DEXA or bone-marker tracking provides the cleanest evaluation. For most compounds the bone effect is secondary and develops over months.

Will Epithalon affect contraceptive efficacy?

For most peptide compounds, contraceptive efficacy is not significantly affected. Compounds directly modulating the HPG axis (kisspeptin, gonadorelin) are exceptions and warrant alternative or additional contraceptive measures during use. Epithalon's specific interaction follows its mechanism.

What is Epithalon?

Epithalon (also known as Epitalon / Epithalamin tetrapeptide) is a 4-residue pineal-derived tetrapeptide with a molecular weight of 390 Da and a plasma half-life of Very short (minutes). Identified by Khavinson in St. Petersburg. Stimulates telomerase activity in somatic cells, with downstream effects on telomere length over multi-year cycles. Normalises age-related decline in pineal melatonin output. Putative epigenetic effects on aging-clock methylation patterns are an active area of investigation. The compound is studied primarily in the female physiology domain for the applications outlined above.

How does Epithalon's half-life affect dosing?

Epithalon has a plasma half-life of Very short (minutes), which is short enough to require multiple daily doses to maintain therapeutic exposure. The receptor occupancy curve under 1x daily for 10-20 day cycles, 1-2x yearly dosing at 5-10 mg per dose explains the typical onset timeline for female hormonal and cyclical endpoints.

Clinical Protocol

Start a Epithalon Protocol

Alukard provides physician-supervised women's health protocols with GMP-certified Epithalon and Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get Protocol

Quick Facts

Molecular weight: 390 Da
Sequence length: 4 aa
Half-life: Very short (minutes)
WADA: Not specifically listed
FDA: Unapproved
Research: Multi-decade Russian research; long-running human cohort studies

Stack Partners

Oxytocin

Kisspeptin

GHK-Cu

PT-141

Research Note

All female physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Epithalon unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised women's health protocols

Start Your Female Physiology Protocol for Epithalon

Alukard provides physician-supervised women's health protocols with Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised